Cargando…

Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience

BACKGROUND: Parathyroid carcinoma (PC) is the rarest endocrine cancer and an infrequent cause of primary hyperparathyroidism (PHPT), responsible for less than 1% of cases. Due to its rarity, treatment is challenging. METHODS: A retrospective cohort study on 462 patients referred for parathyroidectom...

Descripción completa

Detalles Bibliográficos
Autores principales: De Pasquale, Loredana, Bulfamante, Antonio Mario, Felisati, Giovanni, Castellani, Luca, Ghilardi, Giorgio, Saibene, Alberto Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516565/
https://www.ncbi.nlm.nih.gov/pubmed/34659402
http://dx.doi.org/10.1155/2021/5397941
_version_ 1784583831709286400
author De Pasquale, Loredana
Bulfamante, Antonio Mario
Felisati, Giovanni
Castellani, Luca
Ghilardi, Giorgio
Saibene, Alberto Maria
author_facet De Pasquale, Loredana
Bulfamante, Antonio Mario
Felisati, Giovanni
Castellani, Luca
Ghilardi, Giorgio
Saibene, Alberto Maria
author_sort De Pasquale, Loredana
collection PubMed
description BACKGROUND: Parathyroid carcinoma (PC) is the rarest endocrine cancer and an infrequent cause of primary hyperparathyroidism (PHPT), responsible for less than 1% of cases. Due to its rarity, treatment is challenging. METHODS: A retrospective cohort study on 462 patients referred for parathyroidectomy to Thyroid and Parathyroid Unit at Santi Paolo e Carlo Hospital, Milan, Italy, from 2011 to 2021. We identified and individually described the patients affected with PC. Then, we split all patients treated for PHPT into four groups based on the cause: PC, adenoma, atypical adenoma, and hyperplasia. Patients' demographics, preoperative evaluation results, intraoperative findings, and outcomes for the PC group were compared with groups of PHPT due to benign causes. RESULTS: Eight cases of PC were identified, five males and three females. Seven cases presented with symptoms of hypercalcemia and one with a neck mass. Five underwent en bloc resections and three local excisions. Histopathological features showed capsular invasion in four patients, capsular and soft tissue invasion in three patients, and vascular invasion in one case. No patients had distant metastasis. One patient was classed as high risk based on the Schulte classification system. All patients treated for PC were alive and disease-free at a mean follow-up of 38.4 months. When compared with other PHPT patients, PC patients were more frequently male and had higher preoperative blood calcium and PTH and lower phosphate levels, larger and heavier parathyroids excised, lower postoperative calcium, and a higher rate of postoperative hypoparathyroidism. CONCLUSION: Our study highlights some aspects valuable to suspect PC and differentiate PHPT-PC from benign causes of PHPT preoperatively. Preoperative suspicion of malignancy is essential to guarantee the best course of treatment for patients. Although limited for size and follow-up, the excellent outcome of our series seems to support the value of both surgery extension and risk class according to the Schulte classification as possible prognostic factors for recurrence.
format Online
Article
Text
id pubmed-8516565
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-85165652021-10-15 Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience De Pasquale, Loredana Bulfamante, Antonio Mario Felisati, Giovanni Castellani, Luca Ghilardi, Giorgio Saibene, Alberto Maria Int J Endocrinol Research Article BACKGROUND: Parathyroid carcinoma (PC) is the rarest endocrine cancer and an infrequent cause of primary hyperparathyroidism (PHPT), responsible for less than 1% of cases. Due to its rarity, treatment is challenging. METHODS: A retrospective cohort study on 462 patients referred for parathyroidectomy to Thyroid and Parathyroid Unit at Santi Paolo e Carlo Hospital, Milan, Italy, from 2011 to 2021. We identified and individually described the patients affected with PC. Then, we split all patients treated for PHPT into four groups based on the cause: PC, adenoma, atypical adenoma, and hyperplasia. Patients' demographics, preoperative evaluation results, intraoperative findings, and outcomes for the PC group were compared with groups of PHPT due to benign causes. RESULTS: Eight cases of PC were identified, five males and three females. Seven cases presented with symptoms of hypercalcemia and one with a neck mass. Five underwent en bloc resections and three local excisions. Histopathological features showed capsular invasion in four patients, capsular and soft tissue invasion in three patients, and vascular invasion in one case. No patients had distant metastasis. One patient was classed as high risk based on the Schulte classification system. All patients treated for PC were alive and disease-free at a mean follow-up of 38.4 months. When compared with other PHPT patients, PC patients were more frequently male and had higher preoperative blood calcium and PTH and lower phosphate levels, larger and heavier parathyroids excised, lower postoperative calcium, and a higher rate of postoperative hypoparathyroidism. CONCLUSION: Our study highlights some aspects valuable to suspect PC and differentiate PHPT-PC from benign causes of PHPT preoperatively. Preoperative suspicion of malignancy is essential to guarantee the best course of treatment for patients. Although limited for size and follow-up, the excellent outcome of our series seems to support the value of both surgery extension and risk class according to the Schulte classification as possible prognostic factors for recurrence. Hindawi 2021-10-07 /pmc/articles/PMC8516565/ /pubmed/34659402 http://dx.doi.org/10.1155/2021/5397941 Text en Copyright © 2021 Loredana De Pasquale et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
De Pasquale, Loredana
Bulfamante, Antonio Mario
Felisati, Giovanni
Castellani, Luca
Ghilardi, Giorgio
Saibene, Alberto Maria
Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience
title Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience
title_full Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience
title_fullStr Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience
title_full_unstemmed Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience
title_short Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience
title_sort management and outcome of parathyroid carcinoma-induced primary hyperparathyroidism: a single-centre experience
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516565/
https://www.ncbi.nlm.nih.gov/pubmed/34659402
http://dx.doi.org/10.1155/2021/5397941
work_keys_str_mv AT depasqualeloredana managementandoutcomeofparathyroidcarcinomainducedprimaryhyperparathyroidismasinglecentreexperience
AT bulfamanteantoniomario managementandoutcomeofparathyroidcarcinomainducedprimaryhyperparathyroidismasinglecentreexperience
AT felisatigiovanni managementandoutcomeofparathyroidcarcinomainducedprimaryhyperparathyroidismasinglecentreexperience
AT castellaniluca managementandoutcomeofparathyroidcarcinomainducedprimaryhyperparathyroidismasinglecentreexperience
AT ghilardigiorgio managementandoutcomeofparathyroidcarcinomainducedprimaryhyperparathyroidismasinglecentreexperience
AT saibenealbertomaria managementandoutcomeofparathyroidcarcinomainducedprimaryhyperparathyroidismasinglecentreexperience